Triamcinolone Acetonide as an Adjunctive to VPDT in ARMD.

This study is ongoing, but not recruiting participants.

Sponsors and Collaborators:	Canadian Retinal Trials Group University of British Columbia QLT Inc Vancouver Hospital
Information provided by:	Canadian Retinal Trials Group
ClinicalTrials.gov Identifier:	NCT00148551

Purpose

A 24 - month Study looking at the the changes in visual acuity of patients receiving PDT therapy in conjunction with intravitreal triamcinolone.

Condition	Intervention	Phase
Age-Related Macular Degeneration	Drug: Triamcinolone Acetonide	Phase II Phase III

Genetics Home Reference related topics: X-linked juvenile retinoschisis

MedlinePlus related topics: Macular Degeneration

Drug Information available for: Triamcinolone acetonide Triamcinolone Triamcinolone diacetate Triamcinolone hexacetonide Verteporfin

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	Triamcinolone Acetonide as an Adjunctive Treatment to Verteporfin Therapy in Neovascular Age-Related Macular Degeneration: Randomized Placebo-Controlled Clinical Trial.

Further study details as provided by Canadian Retinal Trials Group:

Primary Outcome Measures:

Changes in visual acuity from baseline.

Secondary Outcome Measures:

Change in lesion characteristics from baseline.

Estimated Enrollment:	120
Study Start Date:	January 2004
Estimated Study Completion Date:	March 2008

Detailed Description:

This study will evaluate the effect of Triamcinolone Acetonide in conjunction with photodynamic therapy for the treatment of sub-foveal choroidal neovascular membranes secondary to age-related macular degeneration.

Eligibility

Ages Eligible for Study:	50 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Individuals with predominantly classic, subfoveal CNV secondary to AMD.
No previous PDT Treatment in study eye.

Exclusion Criteria:

CNV from conditions, other than AMD.
Other disease that could be responsible for decreased vision.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00148551

Locations

Canada, British Columbia
Eye Care Centre
Vancouver, British Columbia, Canada

Sponsors and Collaborators

Canadian Retinal Trials Group

University of British Columbia

QLT Inc

Vancouver Hospital

Investigators

Study Director:

David A Maberley, M.D.

University of British Columbia

More Information

Study ID Numbers:	01 (C03 - 0236)
Study First Received:	September 6, 2005
Last Updated:	July 26, 2007
ClinicalTrials.gov Identifier:	NCT00148551
Health Authority:	Canada: Health Canada

Keywords provided by Canadian Retinal Trials Group:

AMD
Triamcinolone
Macular Degeneration

Study placed in the following topic categories:

Triamcinolone Acetonide
Eye Diseases
Triamcinolone
Verteporfin
Retinal Degeneration

Macular Degeneration
Triamcinolone diacetate
Retinal Diseases
Triamcinolone hexacetonide
Retinal degeneration

Additional relevant MeSH terms:

Anti-Inflammatory Agents
Molecular Mechanisms of Pharmacological Action
Immunologic Factors
Therapeutic Uses
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists

Enzyme Inhibitors
Immunosuppressive Agents
Hormones
Glucocorticoids
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009